Information Provided By: 
Fly News Breaks for September 11, 2017
TTPH
Sep 11, 2017 | 11:23 EDT
Piper Jaffray analyst Edward Tenthoff noted that Tetraphase completed enrollment for its Phase 3 trial in complicated Urinary Tract Infection patients ahead of schedule and he believes the data, which could be reported in the first quarter of next year, could enable an sNDA filing, followed by a potential approval in 2020. He keeps an Overweight rating and $14 price target on Tetraphase shares.
News For TTPH From the Last 2 Days
There are no results for your query TTPH
